XTL Biopharmaceuticals Ltd. (H2K2)

Overview

XTL Biopharmaceuticals Ltd. is a prominent figure in the biopharmaceutical industry, primarily focusing on the acquisition and development of innovative pharmaceutical products aimed at treating autoimmune diseases. Originating as Xenograft Technologies Ltd., the company underwent a significant rebranding to its current name, XTL Biopharmaceuticals Ltd., in July 1995, marking a pivotal point in its journey towards advancing healthcare solutions. Since its founding in 1993, XTL Biopharmaceuticals has established its headquarters in Ramat Gan, Israel, from where it orchestrates its pivotal research and development activities. Through a strategic partnership with Yeda Research and Development Company Limited, it has garnered exclusive rights for the research, development, and commercialization of its flagship drug candidate, hCDR1, for multiple indications. This collaboration underscores the company’s commitment to fostering innovation and bringing groundbreaking treatments to the market.

Products and Services

• hCDR1

At the forefront of XTL Biopharmaceuticals' product pipeline is hCDR1, a promising drug candidate tailored for the treatment of autoimmune diseases, with a particular focus on systemic lupus erythematosus and Sjogren's syndrome. Currently in Phase II-ready status, hCDR1 embodies the company’s dedication to addressing unmet medical needs within the autoimmune disease space. Its development is bolstered by an exclusive licensing agreement with Yeda Research and Development Company Limited, enabling comprehensive research, development, and eventual commercialization across various indications. This strategic alliance not only accelerates the drug’s journey towards market authorization but also solidifies XTL’s position as a key player in the development of novel therapies for autoimmune conditions.